This was in line with the findings that blockade of B7H3 core fucosylation enhances the antitumor immune response,15 that PD-L2 glycosylation negatively modulates antitumor immunity,16 that glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity,8 that removal of N-linked glycosylation enhances PD-L1 detection and predicts anti-PD-1/PD-L1 therapeutic efficacy,12 and that triple-negative breast cancer cells can be eradicated by targeting glycosylated PD-L1.11 The gene discussed is CD274; the disease is triple-negative breast carcinoma.